甲氨蝶呤药物不良反应与还原型叶酸载体基因多态性的相关性研究被引量：2

Correlation between the adverse drug reaction of methotrexate and the polymorphisms of reduced folate carrier

导出

摘要目的考察还原叶酸载体基因(RFC1)G80A基因多态性与甲氨蝶呤治疗异位妊娠所致药物不良反应间的相关性。方法收集经甲氨蝶呤治疗后发生药物不良反应的异位妊娠患者104例,用聚合酶链式反应(PCR)与DNA测序技术检测所有患者RFC1 G80A基因分型,分析不同基因型患者甲氨蝶呤治疗后的药物不良反应发生率。结果104例患者的RFC1 G80A基因型分布符合Hardy-Weinberg平衡。AA型患者的口腔溃疡风险是AG型患者的2.46倍,差异有统计学意义(P<0.05)。AA型患者的肝功能异常风险是GG型患者的3.02倍,差异有统计学意义(P<0.05)。RFC1 G80A中AA型、AG型、GG型患者的消化道反应发生率分别为24.14%,10.00%,16.00%,骨髓抑制发生率分别为20.69%,10.00%,12.00%,不同基因型患者的消化道反应和骨髓抑制发生率比较差异无统计学意义(P>0.05)。结论异位妊娠患者的RFC1 G80A基因多态性与甲氨蝶呤所致口腔溃疡与肝功能异常存在相关性。 Objective To evaluate the relationship between the genetic polymorphisms of reduced folate carrier （RFC1） and the incidence of adverse drug reactions of methotrexate in patients with ectopic pregnancy. Methods 104 ectopic pregnancy patients treated with methotrexate were collected. The genetic polymorphisms of RFC1 G80A were analyzed by PCR and DNA sequencing. The relationship between adverse drug reactions of methotrexate and the genetic polymorphisms were analyzed. Results RFC1 G80A polymorphisms were found to be in Hardy- Weinberg equilibrium. There was a significant difference in the incidence of mucositis and hepatic impair among the patients with different genotypes of RFC1 G80A （P 〈 0.05 ）, while there was no difference in the inci- dence of gastrointestinal reaction and myelosuppression （P 〉 0. 05 ）. The incidence rate of gastrointestinal reaction in patients with AA, AG, GG were 24. 14% , 10. 00% and 16. 00%, respectively. The incidence rate of myelosuppression in patients with AA, AG, GG were 20. 69%, 10.00% and 12.00%, respectively. Conclusion RFC1 G80A was linked with the incidence of mucositis and hepatic impair in ectopic pregnancy patients with methotrexate therapy.

作者邓婕陈丽薛恒曾凡湘刘颖史道华

机构地区福建省妇幼保健院福建医科大学教学医院药剂科福建省妇幼保健院福建医科大学教学医院妇科福建省妇幼保健院福建医科大学教学医院检验科

出处《中国临床药理学杂志》 CAS CSCD 北大核心 2016年第16期1474-1476,共3页 The Chinese Journal of Clinical Pharmacology

基金福建省临床重点专科建设基金资助项目(闽卫科教[2012]149号) 福建省卫生厅青年科研课题基金资助项目(2013-2-12)

关键词还原型叶酸载体基因多态性甲氨蝶呤药物不良反应 reduced folate carrier genetic polymorphisms methotrexate adverse drug reaction

分类号 R979.1 [医药卫生—药品]

引文网络
相关文献

参考文献11

1JIANG W, LV S, SUN L, et al. Diagnosis and treatment of retro- peritoneal eetopie pregnancy : Review of the literature [ J ]. Gynecol Obstet Invest, 2014,77 (4) : 205 - 210.
2曾凡湘,史道华,邓婕,刘颖,郑翠仙,黄丽燕.甲氨蝶呤治疗异位妊娠的疗效及其影响因素分析[J].中国临床药理学杂志,2015,31(5):348-350. 被引量：56
3PEREIRA N, BENDER J L, HANCOCK K, et al. Routine monitoring of liver, renal, and hematologic tests after single - or double -dose methotrexate treatment for ectopic pregnancies after in vitro fertilization [J]. JMinimlnvasive Gynecol, 2015, 22 (7): 1266-1270.
4GANAPATHY V, PRASAD P D, GANAPATHY M E, et al. Placental transporters relevant to drug distribution across the maternal - fetal interface [J]. J Pharmacol Exp Ther, 2000,294(2) :413 -420.
5American College of Obstetricians and Gynecologists. ACOG Prac- tice Bulletin No. 94: Medical management of ectopic pregnancy [ J ]. Obstet Gynecol, 2008,111 (6) : 1479 - 1485.
6. CECCHINO G N, ARAUJO JUNIOR E, ELITO JUNIOR J. Metho- trexate for ectopic pregnancy : When and how [ J ]. Arch Gynecol Obstet, 2014, 290 (3) : 417 -423.
7JANSEN G, MAURITZ R, DRORI S, et al. A structurally altered human reduced folate carrier with increased folic acid transport me- diates a novel mechanism of antifolate resistance [ J]. J Biol Chem, 1998,273(46) :30189 -30198.
8LOPEZ - LOPEZ E, BALLESTEROS J, PINAN M A, et al. Poly- morphisms in the methotrexate transport pathway : A new tool for mtx plasma level prediction in pediatric acute lymphoblastic leukemia [J]. Pharnmogenet Genomics, 2013,23(2) :53 -61.
9LIU D Y, LON H K, WANG Y L, et al. Pharmacokinetics, phar- macodynamics and toxicities of methotrexate in healthy and collagen - induced arthritic rats [J]. Biopharm Drug Dispos, 2013,34(4) : 203 - 214.
10HAWWA A F, ALBAWAB A, ROONEY M, et al. Methotrexate polyglutamates as a potential marker of adherence to long - term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross - sectional study [ J ]. Arthritis Res Ther, 2015,17 ( 1 ) :295 - 305.

二级参考文献10

1谢幸.妇产科学[M].北京:人民卫生出版社,2013:274.
2Barnhart KT. Clinical practice. Ectopic pregnancy [ J ]. N Engl J Med, 2009,361 : 379 - 387.
3Food and Drug Administration. Package insert. Methotrexate injec- tion [EB/OL]. http://www, accessdata, fda. gov/drugsatfda docs/label/2011/011719s1171bl, pdf, 2011 - 11 - 04.
4American College of Obstetricians and Gynecologists. ACOG Prac- tice Bulletin No. 94: Medical management of ectopic pregnancy [J]. Obstet Gynecol, 2008,111:1479 - 1485.
5Practice Committee of American Society for Reproductive Medicine. Medical treatment of ectopic pregnancy: a committee opinion [ J ]. Fertil Steril, 2013,100:638 -644.
6Cohen A, Zakar L, Gil Y, et al. Methotrexate success rates in progressing ectopic pregnancies: a reappraisal [ J ]. Am J Obstet Gynecol, 2014,211:128,el -eS.
7Lipscomb GH, McCord ML, Stovall TG, et al. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies [ J]. N Engl J Med, 1999,341 : 1974 - 1978.
8Lipscomb GH, Givens VA, Meyer NL, et al. Previous ectopic pregnancy as a predictor of failure of systemic methotrexate therapy [J]. Fertil Steril, 2004,81:1221 - 1224.
9Lipscomb GH, Gomez IG, Givens VM, et aL Yolk sac on transvag- inal ultrasound as a prognostic indicator in the treatment of ectopic pregnancy with single - dose methotrexate [ J ]. Am J Obstet Gynecol, 2009,200:338, el - el.
10van Mello NM Mol F, Mol BW, et al. Conservative management of tubal ectopic pregnancy [ J ]. Best Pract Res Clin Obstet Gynaecol, 2009,23:509 - 518.